Advanced hepatocellular carcinoma with MET-amplified contained excellent response to Crizotinib: a case report.

Abstract Background: Hepatocellular carcinoma (HCC) is one of the most lethal tumors all over the world. It’s considered with extensive heterogeneity and lacks therapeutic decision-making biomarkers. There are many novel therapeutic strategies tried to prolong the survival of advanced HCC. Next-generation sequencing (NGS) is generally used for helping treatment decision which help patient benefit from genome-directed targeted. Case presentation: A 56 years-old male with more than 20 years of type-B hepatitis was admitted to our department who underwent laparoscopic hepatic left lateral lobectomy because hepatocellular carcinoma. Unfortunately, tumor recurrence 1 year later. Though multiple treatments were taken, including interventional therapy, tyrosine kinase inhibitor, radiotherapy and immunotherapy, the tumor invaded his 5th thoracic vertebras and leaded to hypoesthesia and hypokinesia below the nipple line plane 2 years later. NGS was used to find potential therapeutic biomarkers. As the met amplification was identified, Crizotinib, the inhibitor of the C-Met was recommended. Tumor reduction and decreased tumor marker were observed immediately in 1 month later. And the patient has remained on remission since then. Conclusions: We reported a patient with high MET amplification benefited from MET inhibitors which recommended by NGS. It indicated the potential clinical decision support value of NGS and the satisfactory treatment effect of C-met inhibitor.